Vendor, Leiden, NLD, part of Johnson & Johnson
Janssen Vaccines & Prevention B.V.
UEI VRE2EKNJTJJ4, CAGE H1N64
3 awards and -$620,809 obligated between March 7, 2024 and October 2, 2025, 100% under full and open competition, against 2.3 offers on average where reported.
Sells to
Awarding agencies by dollars.
| National Institutes of Health | $0 |
| Office of Assistant Secretary for Preparedness and Response | -$620,809 |
Industries
NAICS on the awards, by dollars.
| Professional, Scientific, and Technical ServicesNAICS 541712 | $0 |
| Professional, Scientific, and Technical ServicesNAICS 541711 | -$620,809 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 3 |
| Definitive Contract | 3 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HHSN272200800056CDefinitive Contract, June 27, 2024, Full and Open Competition, 4 offers | National Institutes of Health NiaidNational Institutes of Health | Advanced Development of Multivalent Filovirus (Ebola and Marburg) Hemorrhagic Fever VaccinesNAICS 541712, PSC AN13 | $0 |
| HHSO100201700013CDefinitive Contract, March 7, 2024, Full and Open Competition, 2 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | The Purpose of This Modification Is to Update Key Personnel and Change the Submission of the Monthly Report to Quarterly.NAICS 541711, PSC 6505 | $0 |
| HHSO100201500008CDefinitive Contract, September 13, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | De-Obligate FY24 Canceling Funds.NAICS 541711, PSC AN13 | -$620,809 |
- Product and service codes
- 6505 Drugs and BiologicalsAN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 7 across 3 awards